Dose selection in phase I studies: why we should always go for the most effective

J Clin Oncol. 2008 Jul 20;26(21):3650-2; author reply 3652-3. doi: 10.1200/JCO.2008.17.6719.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Clinical Trials, Phase I as Topic / methods*
  • Dose-Response Relationship, Drug
  • Humans
  • Maximum Tolerated Dose*
  • Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents